前沿速览031期| CAR-T治B淋 前沿览新知
01
CD19 CAR-T细胞治疗后的侵袭性淋巴瘤
Aggressive Lymphoma after CD19 CAR T-Cell Therapy
第一作者：Kobbe G
N Engl J Med. 2024 Oct 3;391(13):1217-1226.
全文网址：https://www.nejm.org/doi/10.1056/NEJMoa2402730?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
02
接受CAR-T治疗的多发性骨髓瘤和淋巴瘤患者的心血管并发症及其与短期和长期疗效的关系
Cardiovascular Complications and Their Association With Short- and Long-Term Outcomes in Patients With Multiple Myeloma and Lymphoma Undergoing Chimeric Antigen Receptor T-Cell Therapy
第一作者：Itzhaki Ben Zadok O
Circulation. 2024 Nov 26;150(22):1815-1817.
全文网址：https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.070432?url_ver=Z39.88-2003&rfr_id=ori:rid:crossref.org&rfr_dat=cr_pub%20%200pubmed
03
通过使用可切换适配器间接靶向抗原，可改善CAR-T细胞治疗的安全性
Improved safety of chimeric antigen receptor T cells indirectly targeting antigens via switchable adapters
第一作者：Park HB
Nat Commun. 2024 Nov 18;15(1):9917.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11574259/
04
复发/难治性弥漫性大B细胞淋巴瘤患者接受CAR-T细胞疗法后使用Loncastuximab的临床结局
Outcomes with loncastuximab tesirine following CAR T-cell therapy in patients with relapsed or refractory diffuse large B-cell lymphoma
第一作者：Epperla N
Blood Cancer J. 2024 Nov 28;14(1):210.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11604956/
05
ARI0003：共同转导的CD19/BCMA双靶点CAR-T细胞用于治疗非霍奇金淋巴瘤
ARI0003: Co-transduced CD19/BCMA Dual-targeting CAR-T Cells for the Treatment of Non-Hodgkin Lymphoma
第一作者：Bachiller M
Mol Ther. 2024 Nov 19:S1525-0016(24)00755-X.
全文网址：https://linkinghub.elsevier.com/retrieve/pii/S1525-0016(24)00755-X
06
CD19 CAR-T细胞治疗后肾损伤的预测因素和启示
Predictors and implications of renal injury after CD19 chimeric antigen receptor T-cell therapy
第一作者：Boardman AP
Haematologica. 2024 Nov 21.
全文网址：https://haematologica.org/article/view/11835
07
既往CAR-T细胞治疗对Mosunetuzumab在复发/难治性B细胞淋巴瘤患者中疗效的影响
Impact of prior CAR-T cell therapy on mosunetuzumab efficacy in patients with relapsed or refractory B-cell lymphomas
第一作者：Chong EA
Blood Adv. 2024 Nov 21:bloodadvances.2024013640.
全文网址：https://ashpublications.org/bloodadvances/article/doi/10.1182/bloodadvances.2024013640/526100/Impact-of-prior-CAR-T-cell-therapy-on
08
原发性中枢神经系统淋巴瘤的研究进展
Advances in Primary Central Nervous System Lymphoma
第一作者：Therkelsen KE
Curr Neurol Neurosci Rep. 2024 Nov 25;25(1):5.
全文网址：https://link.springer.com/article/10.1007/s11910-024-01389-0
09
接受CD19 CAR-T细胞治疗成年患者的神经毒性严重程度可通过脑电图特征和synek量表评估
EEG features and synek scale indicate severity of neurotoxicity in adult patients treated with CD19 CAR T-cell therapy
第一作者：Mao D
Sci Rep. 2024 Nov 23;14(1):29090.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11585625/
10
接受CAR-T细胞治疗的B细胞淋巴瘤患者的生存率、神经毒性和缓解情况可通过基于成像特征的模型来预测
Predicting survival, neurotoxicity and response in B-cell lymphoma patients treated with CAR-T therapy using an imaging features-based model
第一作者：Ferrer-Lores B
EJNMMI Res. 2024 Nov 20;14(1):113.
全文网址：https://pmc.ncbi.nlm.nih.gov/articles/PMC11579271/
免责声明：本资料为专业医学资料，旨在促进医药信息的沟通和交流，仅供医疗卫生专业人士参考；任何处方请参考产品最新详细处方资料。本文件可能包含涉及医学情况、健康及治疗方法的信息。相关信息不得用作诊断或治疗，不能替代专业医学意见。
审批编号：NP-NHL-2024.12-2 valid until 2026.2
供稿与审核：临床开发与医学部